Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States.

Marqueen KE, Waingankar N, Sfakianos JP, Mehrazin R, Niglio SA, Audenet F, Jia R, Mazumdar M, Ferket BS, Galsky MD.

JNCI Cancer Spectr. 2018 Nov;2(4):pky075. doi: 10.1093/jncics/pky075. Epub 2019 Jan 28.

2.

A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.

Audenet F, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE, Gin GE.

Urol Oncol. 2019 Feb;37(2):116-122. doi: 10.1016/j.urolonc.2018.11.011. Epub 2018 Dec 1.

PMID:
30509868
3.

[French ccAFU guidelines - Update 2018-2020: Bladder cancer].

Rouprêt M, Neuzillet Y, Pignot G, Compérat E, Audenet F, Houédé N, Larré S, Masson-Lecomte A, Colin P, Brunelle S, Xylinas E, Roumiguié M, Méjean A.

Prog Urol. 2018 Nov;28(12S):S46-S78. doi: 10.1016/j.purol.2018.07.283. Epub 2018 Oct 23. Review. French.

PMID:
30366708
4.

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.

Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB.

Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039. Epub 2018 Oct 23.

PMID:
30352907
5.

[French ccAFU guidelines - Update 2018-2020: Upper tract urothelial carcinoma].

Rouprêt M, Xylinas E, Colin P, Houédé N, Compérat E, Audenet F, Larré S, Masson-Lecomte A, Pignot G, Brunelle S, Roumiguié M, Neuzillet Y, Méjean A.

Prog Urol. 2018 Nov;28(12S):S32-S45. doi: 10.1016/j.purol.2018.07.284. Epub 2018 Oct 11. Review. French.

PMID:
30318333
6.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.

Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.

PMID:
30290956
7.

[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].

Pignot G, Houédé N, Roumiguié M, Audenet F, Brunelle S, Colin P, Compérat E, Larré S, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A, Rouprêt M; les membres du CCAFU Vessie.

Prog Urol. 2018 Oct;28(12):567-574. doi: 10.1016/j.purol.2018.07.003. Epub 2018 Sep 8. Review. French.

PMID:
30205925
8.

Dealing with perioperative antiplatelet treatment for transurethral resection of the bladder: primum non nocere.

Audenet F, Sfakianos JP.

Transl Androl Urol. 2018 May;7(Suppl 2):S258-S259. doi: 10.21037/tau.2018.03.24. No abstract available.

9.

Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.

Audenet F, Waingankar N, Ferket BS, Niglio SA, Marqueen KE, Sfakianos JP, Galsky MD.

J Urol. 2018 Nov;200(5):996-1004. doi: 10.1016/j.juro.2018.06.001. Epub 2018 Jun 4.

PMID:
29879397
10.

Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.

Audenet F, Farkas AM, Anastos H, Galsky MD, Bhardwaj N, Sfakianos JP.

World J Urol. 2018 Nov;36(11):1741-1748. doi: 10.1007/s00345-018-2359-7. Epub 2018 Jun 2.

PMID:
29860605
11.

Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study).

Nouhaud FX, Bernhard JC, Bigot P, Khene ZE, Audenet F, Lang H, Bergerat S, Fraisse G, Grenier N, Cornelis F, Nedelcu C, Béjar S, Fromont-Hankard G, Allory Y, Lindner V, Verkarre V, Daniel L, Yacoub M, Correas JM, Méjean A, Rioux-Leclercq N, Bensalah K.

World J Urol. 2018 Oct;36(10):1643-1649. doi: 10.1007/s00345-018-2307-6. Epub 2018 May 5.

PMID:
29730837
12.

Nephron sparing surgery in tumours greater than 7cm.

de Saint Aubert N, Audenet F, Mccaig F, Delavaud C, Verkarre V, Le Guilchet T, Dariane C, Pettenati C, Slaoui H, Mejean A, Timsit MO.

Prog Urol. 2018 May;28(6):336-343. doi: 10.1016/j.purol.2018.03.009. Epub 2018 Apr 23.

PMID:
29699856
13.

Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.

Isharwal S, Huang H, Nanjangud G, Audenet F, Chen YB, Gopalan A, Fine SW, Tickoo SK, Lee BH, Iyer G, Chadalavada K, Rosenberg JE, Bajorin DF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA.

Hum Pathol. 2018 Jul;77:63-69. doi: 10.1016/j.humpath.2018.03.015. Epub 2018 Mar 27.

PMID:
29601842
14.

The evolution of bladder cancer genomics: What have we learned and how can we use it?

Audenet F, Attalla K, Sfakianos JP.

Urol Oncol. 2018 Jul;36(7):313-320. doi: 10.1016/j.urolonc.2018.02.017. Epub 2018 Mar 21. Review.

PMID:
29573965
15.

Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens.

Bagrodia A, Audenet F, Pietzak EJ, Kim K, Murray KS, Cha EK, Sfakianos JP, Iyer G, Singla N, Arcila M, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol Focus. 2018 Jan 30. pii: S2405-4569(18)30006-3. doi: 10.1016/j.euf.2018.01.005. [Epub ahead of print]

PMID:
29396293
16.

Psychosocial impact of penile carcinoma.

Audenet F, Sfakianos JP.

Transl Androl Urol. 2017 Oct;6(5):874-878. doi: 10.21037/tau.2017.07.24. Review.

17.

[Comparison of operative and oncologic results between partial nephrectomy and radiofrequency ablation for treatment of renal tumors in patients older than 75].

Cholley I, Correas JM, Masson-Lecomte A, Sanchez S, Champy C, Le Guilchet T, Ariane M, Hurel S, Audenet F, Thiounn N, Fontaine E, Mejean A, Timsit MO.

Prog Urol. 2018 Jan;28(1):55-61. doi: 10.1016/j.purol.2017.10.006. Epub 2017 Nov 22. French.

PMID:
29174691
18.

Evidence of Atypical Recurrences After Robot-Assisted Radical Cystectomy: A Comprehensive Review of the Literature.

Audenet F, Sfakianos JP.

Bladder Cancer. 2017 Oct 27;3(4):231-236. doi: 10.3233/BLC-170127. Review.

19.

[Retrospective comparison of the reproducibility and the performances of R.E.N.A.L. score, 12 segments score and UPRCC score for the partial nephrectomy].

Gury-Coupier L, Audenet F, Delavaud C, Timsit MO, Mejean A.

Prog Urol. 2017 Dec;27(16):1050-1057. doi: 10.1016/j.purol.2017.09.007. Epub 2017 Oct 31. French.

PMID:
29097040
20.

Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.

Audenet F, Vertosick EA, Fine SW, Sjoberg DD, Vickers AJ, Reuter VE, Eastham JA, Scardino PT, Touijer KA.

J Urol. 2018 Apr;199(4):961-968. doi: 10.1016/j.juro.2017.10.010. Epub 2017 Oct 10.

PMID:
29030317
21.

Pathological heterogeneity in sporadic synchronous renal tumors: Is the histological concordance predictable?

Beaugerie A, Audenet F, Verkarre V, Delavaud C, Le Guilchet T, Hurel S, de Saint Aubert N, Correas JM, Fontaine E, Richard S, Méjean A, Timsit MO.

Urol Oncol. 2018 Jan;36(1):11.e7-11.e12. doi: 10.1016/j.urolonc.2017.09.002. Epub 2017 Oct 6.

PMID:
28993058
22.

Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.

Isharwal S, Audenet F, Drill E, Pietzak EJ, Iyer G, Ostrovnaya I, Cha E, Donahue T, Arcila M, Jayakumaran G, Berger MF, Rosenberg JE, Bajorin DF, Coleman J, Dalbagni G, Reuter VE, Bochner BH, Solit DB, Al-Ahmadie HA.

Eur Urol Focus. 2017 Aug 10. pii: S2405-4569(17)30189-X. doi: 10.1016/j.euf.2017.07.004. [Epub ahead of print]

23.

Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?

Audenet F, Retinger C, Chien C, Benfante NE, Bochner BH, Donat SM, Herr HW, Dalbagni G.

Urol Oncol. 2017 Oct;35(10):603.e1-603.e5. doi: 10.1016/j.urolonc.2017.06.042. Epub 2017 Jul 6.

24.

Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance.

Audenet F, Rozet F, Resche-Rigon M, Bernard R, Ingels A, Prapotnich D, Sanchez-Salas R, Galiano M, Barret E, Cathelineau X.

Clin Genitourin Cancer. 2017 Dec;15(6):e907-e913. doi: 10.1016/j.clgc.2017.04.024. Epub 2017 Apr 26.

PMID:
28522288
25.

Prospective assessment and histological analysis of adherent perinephric fat in partial nephrectomies.

Dariane C, Le Guilchet T, Hurel S, Audenet F, Beaugerie A, Badoual C, Tordjman J, Clément K, Urien S, Pietak M, Fontaine E, Méjean A, Timsit MO.

Urol Oncol. 2017 Feb;35(2):39.e9-39.e17. doi: 10.1016/j.urolonc.2016.09.008. Epub 2016 Oct 27.

PMID:
28341496
26.

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F.

Cancer Treat Rev. 2017 Apr;55:211-217. doi: 10.1016/j.ctrv.2016.09.008. Epub 2016 Sep 10. Review.

27.

[Cancer genetic screening for patient with multiple renal tumors: What is the current practice for what results?].

Beaugerie A, Verkarre V, Audenet F, Le Guilchet T, Hurel S, Richard S, Corréas JM, Fontaine E, Méjean A, Timsit MO.

Prog Urol. 2016 Jun;26(8):442-9. doi: 10.1016/j.purol.2016.06.001. Epub 2016 Jul 26. French.

PMID:
27473786
28.

Percutaneous Renal Biopsies for Small Renal Masses: Complex Tumors on Nephrometry Should Be the First Targets.

Ingels A, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Lenoir S, Weber N, Audenet F, Cathelineau X.

Clin Genitourin Cancer. 2016 Oct;14(5):e457-e462. doi: 10.1016/j.clgc.2016.02.006. Epub 2016 Feb 21.

PMID:
27025355
29.

[Conservative management of upper tract urinary fistulae using ureteral trans-vesico-parietal stent].

Le Guilchet T, Audenet F, Hurel S, Beaugerie A, Fontaine E, Terrier N, Timsit MO, Mejean A.

Prog Urol. 2016 Mar;26(3):152-8. doi: 10.1016/j.purol.2016.01.005. Epub 2016 Feb 10. French.

PMID:
26874826
30.

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.

Eur J Cancer. 2016 Feb;54:69-74. doi: 10.1016/j.ejca.2015.11.017. Epub 2015 Dec 25.

PMID:
26724422
31.

Robot-Assisted Laparoscopic Partial Colpectomy and Intracorporeal Ileal Conduit Urinary Diversion (Bricker) for Cervical Adenocarcinoma Recurrence.

Uzan J, Cornou C, Bensaid C, Audenet F, Ngô C, Bats AS, Lecuru F.

Case Rep Obstet Gynecol. 2015;2015:241094. doi: 10.1155/2015/241094. Epub 2015 Nov 8.

32.

Comparaison de la chirurgie conservatrice vs ablation par radiofréquence pour le traitement du carcinome à cellules rénales après 75ans.

Cholley I, Correas J, Sanchez S, Ariane M, Fontaine E, Thiounn N, Hurel S, Le Guilchet T, Champy C, Audenet F, Pietak M, Méjean A, Timsit M.

Prog Urol. 2015 Nov;25(13):827-8. doi: 10.1016/j.purol.2015.08.220. French. No abstract available.

PMID:
26544414
33.

Comparaison des résultats de la chirurgie conservatrice vs totale dans le traitement des carcinomes à cellules rénales classés cT2.

De Saint Aubert N, Méjean A, Verkarre V, Fontaine E, Ariane M, Audenet F, Timsit M.

Prog Urol. 2015 Nov;25(13):825-6. doi: 10.1016/j.purol.2015.08.218. French. No abstract available.

PMID:
26544412
34.

Traitement conservateur des fistules urinaires du haut appareil par sonde urétérale trans-vésico-pariétale mise en place par voie percutanée.

Le Guilchet T, Audenet F, Hurel S, Beaugerie A, Fontaine E, Terrier N, Timsit M, Mejean A.

Prog Urol. 2015 Nov;25(13):818. doi: 10.1016/j.purol.2015.08.207. French. No abstract available.

PMID:
26544402
35.

Particularités de la chirurgie pour tumeurs rénales chez les patients de moins de 40ans.

Wiedemann L, Audenet F, Le Guilchet T, Hurel S, Beaugerie A, Fontaine E, Timsit M, Mejean A.

Prog Urol. 2015 Nov;25(13):799. doi: 10.1016/j.purol.2015.08.166. French. No abstract available.

PMID:
26544361
36.

Le score de Charlson est associé aux complications post-opératoires lors de la prise en charge chirurgicale des petites masses rénales.

Batista da Costa J, Audenet F, Le Guilchet T, Hurel S, Beaugerie A, Fontaine E, Timsit M, Mejean A.

Prog Urol. 2015 Nov;25(13):745-6. doi: 10.1016/j.purol.2015.08.060. French. No abstract available.

PMID:
26544254
37.

Une nouvelle approche pour l'adénomectomie laparoscopique : la voie trans-cervicale.

Mandron E, Audenet F, Dandrea M, Timsit M, Mejean A.

Prog Urol. 2014 Nov;24(13):899. doi: 10.1016/j.purol.2014.09.026. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461785
38.

Accessibilité prévisible au post-internat d'urologie jusqu'en 2016.

Celhay O, Brichart N, Audenet F, Capon G, Dariane C, Fiard G, Lebdaï S, Madec F, Maurin C, Sanson S, Rizk J, Tanchoux C, Thibault F, Terrasa J, Murez T, Terrier J.

Prog Urol. 2014 Nov;24(13):836. doi: 10.1016/j.purol.2014.08.116. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461644
39.

Tumeurs du rein multiples sporadiques : quelle concordance histologique ?

Beaugerie A, Verkarre V, Ariane M, Audenet F, Corréas J, Vasiliu V, Richard S, Méjean A, Timsit M.

Prog Urol. 2014 Nov;24(13):834. doi: 10.1016/j.purol.2014.08.112. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461639
40.

Dépistage oncogénétique dans les tumeurs du rein multiples : quelle pratique ? Quels résultats ?

Beaugerie A, Verkarre V, Ariane M, Audenet F, Corréas J, Vasiliu V, Richard S, Méjean A, Timsit M.

Prog Urol. 2014 Nov;24(13):834-5. doi: 10.1016/j.purol.2014.08.113. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461638
41.

Complications urologiques après traitement percutané des tumeurs du rein.

Audenet F, Khairoune A, Timsit M, Sadfi A, Helenon O, Mejean A, Correas J.

Prog Urol. 2014 Nov;24(13):825-6. doi: 10.1016/j.purol.2014.08.095. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461620
42.

La tumorectomie rénale remplit aussi bien les objectifs du « TRIFECTA » que la néphrectomie élargie lors de la prise en charge des carcinomes à cellules rénales pT3a de découverte fortuite.

Champy C, Audenet F, Timsit M, Ariane M, Le Guilchet T, Hurel S, Fontaine E, Mejean A.

Prog Urol. 2014 Nov;24(13):824. doi: 10.1016/j.purol.2014.08.092. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461618
43.

IRM multiparamétrique et élastographie ultrasonore par ondes de cisaillement dans le diagnostic du cancer de prostate : performances relatives.

Correas J, Khairoune A, Audenet F, Tissier A, Timsit M, Mejean A, Helenon O.

Prog Urol. 2014 Nov;24(13):814-5. doi: 10.1016/j.purol.2014.08.071. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461596
44.

What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?

Lebdai S, Basset V, Branchereau J, de La Taille A, Flamand V, Lebret T, Murez T, Neuzillet Y, Ploussard G, Audenet F.

World J Urol. 2016 May;34(5):617-24. doi: 10.1007/s00345-015-1687-0. Epub 2015 Sep 15. Review.

PMID:
26373956
45.

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ.

Urol Oncol. 2015 Aug;33(8):339.e9-15. doi: 10.1016/j.urolonc.2015.05.014. Epub 2015 Jun 16.

PMID:
26087971
46.

Re: Alessandro Volpe, Kamran Ahmed, Prokar Dasgupta, et al. Pilot Validation Study of the European Association of Urology Robotic Training Curriculum. Eur Urol 2015;68:292-9.

Oderda M, Audenet F, Briganti A, Brown M, De Marco V, Gan M, Janssen M, Navarro R, Sanchez-Salas R, Wit E.

Eur Urol. 2015 Aug;68(2):e29-30. doi: 10.1016/j.eururo.2014.11.047. Epub 2014 Dec 6. No abstract available.

PMID:
25488680
47.

[Predictable access to the fellowship of urology in France till 2016: an update of the AFUF].

Celhay O, Brichart N, Audenet F, Capon G, Dariane C, Fiard G, Lebdai S, Madec FX, Maurin C, Sanson S, Rizk J, Tanchoux C, Thibault F, Terrasa JB, Murez T, Terrier JÉ.

Prog Urol. 2014 Sep;24(10):658-64. doi: 10.1016/j.purol.2014.04.004. Epub 2014 Jun 2. French.

PMID:
25214296
48.

[Non-surgical treatment modalities available for the treatment of upper tract urothelial carcinomas: state-of-the-art review for the yearly scientific report of the French National Association of Urology].

Audenet F, Rouprêt M, Houédé N, Colin P.

Prog Urol. 2014 Nov;24(15):1030-40. doi: 10.1016/j.purol.2014.07.002. Epub 2014 Aug 27. Review. French.

PMID:
25208728
49.

[Current state of compensation of on-duty and on-call urologists in France: a study from AFUF].

Dariane C, Rizk J, Meyer F, Audenet F, Brichart N, Capon G, Fiard G, Lebdai S, Madec FX, Maurin C, Murez T, Sanson S, Tanchoux C, Terrasa JB, Thibault F, Terrier JE.

Prog Urol. 2014 Jun;24(7):456-62. doi: 10.1016/j.purol.2013.11.009. Epub 2013 Dec 27. French.

PMID:
24861686
50.

[The role of simulation in the curriculum of French urologists-in-training: a study by the French Association of Urologists-in-Training (AFUF)].

Fiard G, Capon G, Rizk J, Maurin C, Dariane C, Audenet F, Tanchoux C, Brichart N, Lebdai S, Sanson S, Madec FX, Thibault F, Terrasa JB, Murez T, Terrier JE.

Prog Urol. 2014 May;24(6):390-6. doi: 10.1016/j.purol.2013.10.013. Epub 2013 Dec 2. French.

PMID:
24821563

Supplemental Content

Loading ...
Support Center